Ultragenyx, Mereo Report 14-Month Results From Phase 2 Portion Of Phase 2/3 Orbit Study; Treatment With Setrusumab Resulted In Sustained 67% Reduction In Annualized Fracture Rate In Osteogenesis Imperfecta Patients
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx and Mereo reported positive 14-month results from the Phase 2 portion of their Phase 2/3 Orbit study. Treatment with setrusumab (UX143) resulted in a sustained 67% reduction in the annualized fracture rate in osteogenesis imperfecta (OI) patients and significant improvements in lumbar spine bone mineral density (BMD) at month 12.
June 11, 2024 | 9:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mereo reported positive 14-month results for setrusumab in OI patients, showing a 67% reduction in fracture rate and improved BMD.
The positive results from the Phase 2 portion of the Phase 2/3 Orbit study are likely to boost investor confidence in Mereo, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Ultragenyx reported positive 14-month results for setrusumab in OI patients, showing a 67% reduction in fracture rate and improved BMD.
The positive results from the Phase 2 portion of the Phase 2/3 Orbit study are likely to boost investor confidence in Ultragenyx, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100